We advised METiS TechBio on its IPO and HKEX listing

Davis Polk advised METiS TechBio on its initial public offering and listing on the Hong Kong Stock Exchange in reliance on Rule 144A and Regulation S. The gross proceeds from the offering amounted to approximately HK$2.43 billion, assuming the over-allotment option will be exercised in full.

METiS TechBio is a pioneer in AI-empowered nanomaterial innovation, dedicated to the delivery and application of functional payloads across life forms with the commitment to unlocking a healthier world through AI-driven nanotechnology. Founded by a team of MIT-trained scientists with deep expertise in AI, quantum mechanics, nanomaterials and advanced drug delivery, the company has developed three proprietary platform technologies: AiLNP (AI Nano Delivery System Design Platform), AiRNA (AI mRNA Sequence Design Platform) and AiTEM (AI Small Molecule Formulation Design Platform).

The Davis Polk corporate team included partners Li He, Jason Xu and Xuelin (Steve) Wang, counsel – registered foreign lawyer Xin (Sheen) Xu, counsel Wendy Kan and associates Sarah Shi and Andrew Pu. Counsel Alon Gurfinkel and associate Kelli A. Rivers provided tax advice. Counsel Matthew R. Silver provided advice regarding the Investment Company Act of 1940. Members of the Davis Polk team are based in the Hong Kong, Beijing, New York and London offices.

Copy link to share post